You just read:

Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS

News provided by

Mylan N.V. , Theravance Biopharma, Inc.

May 23, 2017, 09:15 ET